A retrospective study evaluating efficacy of dose reduction of first line pazopanib in patients with metastatic renal cell carcinoma

Trial Profile

A retrospective study evaluating efficacy of dose reduction of first line pazopanib in patients with metastatic renal cell carcinoma

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Aug 2017 Results assessing efficacy of dose reduction of first line pazopanib in patients with metastatic renal cell carcinoma published in the Drugs in R and D
    • 24 Mar 2017 New trial record
    • 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top